Want to see OM full AI Analyst Report?
OM Stock Chart & Stats
$4.04
$0.28(6.93%)
At close: 4:00 PM EDT
$4.04
$0.28(6.93%)
Day’s Range― - ―
52-Week Range$3.00 - $18.19
Previous Close$4.32
Volume70.14K
Average Volume (3M)259.55K
Market Cap
$79.99M
Enterprise Value$15.46
Total Cash (Recent Filing)$156.71M
Total Debt (Recent Filing)$101.61M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Aug 06, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.16
Shares Outstanding18,537,241
10 Day Avg. Volume125,119
30 Day Avg. Volume259,552
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.47
P/FCF Ratio-1.20
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.67Price Target Upside89.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.91
Revenue Forecast (FY)$126.60M
Bulls Say, Bears Say
Bulls Say
High Recurring Revenue MixA ~70% recurring revenue mix from consumables and service creates predictable, repeatable cash flows that scale with treatments and installed base growth. This structural revenue stickiness reduces top-line volatility and supports margin stability and long-term customer retention across care settings.
Material Gross Margin ExpansionSustained gross margin improvement and high product margins indicate stronger unit economics and pricing/production leverage. Higher margins improve cash conversion potential, lower required scale to breakeven, and provide durable room for reinvestment in sales, R&D, and commercialization over the medium term.
Clean Balance Sheet And Cash RunwayVery low debt and positive equity provide financial flexibility while the company invests in commercialization. Combined with a sizable cash balance noted elsewhere, this balance-sheet positioning reduces near-term financing risk and gives multi-quarter runway to execute product launches and expand installed base.
Bears Say
Deep Unprofitability And Negative Cash FlowLarge trailing losses and persistent negative free cash flow mean the business still depends on capital or substantial margin improvement to reach self-sustaining operations. Continued negative cash generation raises execution and funding risks if revenue growth or margin trends stall.
Revenue Softness And Lumpiness In Capital SalesDependence on sporadic capital orders creates quarter-to-quarter revenue volatility and complicates forecasting and cash planning. Product sales declines signal adoption timing risk; if capital placements do not normalize, recurring revenue may take longer to scale and margins may remain pressured.
Reliance On Next‑gen Tableau RolloutMaterial growth and back-half revenue assumptions hinge on the next-gen Tableau launch and its cybersecurity positioning. Delays, slower adoption, or weaker-than-expected uptake would undermine projected demand, compress expected margin gains, and extend the timeline to profitability.
Outset Medical News
OM FAQ
What was Outset Medical, Inc.’s price range in the past 12 months?
Outset Medical, Inc. lowest stock price was $3.00 and its highest was $18.18 in the past 12 months.
What is Outset Medical, Inc.’s market cap?
Outset Medical, Inc.’s market cap is $79.99M.
When is Outset Medical, Inc.’s upcoming earnings report date?
Outset Medical, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 7 days.
How were Outset Medical, Inc.’s earnings last quarter?
Outset Medical, Inc. released its earnings results on May 07, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.79 by -$0.04.
Is Outset Medical, Inc. overvalued?
According to Wall Street analysts Outset Medical, Inc.’s price is currently Undervalued.
Does Outset Medical, Inc. pay dividends?
Outset Medical, Inc. does not currently pay dividends.
What is Outset Medical, Inc.’s EPS estimate?
Outset Medical, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Outset Medical, Inc. have?
Outset Medical, Inc. has 18,537,241 shares outstanding.
What happened to Outset Medical, Inc.’s price movement after its last earnings report?
Outset Medical, Inc. reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.79. Following the earnings report the stock price went down -21.047%.
Which hedge fund is a major shareholder of Outset Medical, Inc.?
Currently, no hedge funds are holding shares in OM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outset Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.67 (89.77% Upside)
$7.67 (89.77% Upside)
Blogger Sentiment
Bullish
OM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.18%
Trailing 12-Months
Company Description
Outset Medical, Inc.
Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts integrated water purification, on-demand production of dialysate, and advanced software complete with connectivity features. Founded in 2003, the company initially operated under the name Home Dialysis Plus, Ltd. before rebranding to Outset Medical, Inc. in January 2015. Its corporate headquarters are located in San Jose, California.
OM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial trajectory: substantial gross margin expansion (620 bps), a 32% improvement in non-GAAP net loss, strong cash balance ($161M) with lower-than-expected cash burn, and a strategic next-generation product and experienced commercial hire poised to drive future demand. Offsetting these positives were a 6% year-over-year revenue decline in Q1 driven by lumpiness in capital orders (product revenue down 13%), modestly higher operating expenses, and reliance on the timing and success of the next-gen Tableau launch to deliver back-half revenue. On balance, the positive margin, cash, and operational execution updates outweigh the timing-related revenue headwinds.View all OM earnings summariesOM Revenue Breakdown
47.04% Consoles
32.37% Consumables
20.59% Service and other revenue
OM Stock 12 Month Forecast
Average Price Target
$7.67
▲(89.77% Upside)
Technical Analysis
Ownership Overview
19.26% Insiders
21.41% Mutual Funds
3.89% Other Institutional Investors
50.34% Public Companies and
Individual Investors